What is the latest NURECA stock price?
The latest stored price for NURECA is Rs 305.00 as of 2026-11-03.
gimli
NURECA stock AI analysis
NURECA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
NURECA LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available NURECA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹305.00
1W return
+2.38%
1M return
-12.82%
3M return
-8.52%
6M return
+14.44%
1Y return
+19.35%
Market cap
₹291.03 cr
PE
61.14
PB
1.55
ROE
+2.54%
ROCE
+5.31%
RSI
42.13
Turnover
₹0.17 cr
Why it can matter in screens
- Momentum: NURECA is below 50DMA, above 200DMA; RSI is 42.13.
- Returns: 1D +2.18%, 1W +2.38%, 1M -12.82%, 3M -8.52%, 1Y +19.35%.
- Trend levels: 52W high ₹376.00, 52W low ₹224.02, off high -18.88%.
- Liquidity: latest turnover is ₹0.17 cr; volume vs 20D is +1.09%.
- Valuation/profitability: PE 61.14, PB 1.55, ROE +2.54%, ROCE +5.31%.
- Growth: 3Y sales CAGR +9.70%, 3Y profit CAGR n/a.
Quick Answers
Is NURECA above its 50DMA and 200DMA?
NURECA is below 50DMA, above 200DMA. The latest 50DMA is 326.95 and the latest 200DMA is 286.14.
What are NURECA PE, ROE and ROCE?
NURECA has PE 61.14, ROE +2.54%, and ROCE +5.31% in Gimli's latest available snapshot.
How has NURECA performed recently?
NURECA has returned -12.82% over 1 month, -8.52% over 3 months, and +19.35% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-09-30 | 58.53 cr | 6.58 cr | 4.05 cr | 4.25 |
| 2026-06-30 | 40.34 cr | 5.24 cr | 3.07 cr | 3.21 |
| 2026-03-31 | 35.41 cr | -4.76 cr | -6.09 cr | -6.45 |
| 2025-12-31 | 39.64 cr | 5.44 cr | 3.73 cr | 3.91 |
| 2025-09-30 | 40.22 cr | 5.00 cr | 3.14 cr | nan |
| 2025-06-30 | 34.18 cr | 2.01 cr | 0.81 cr | 0.81 |
| 2025-03-31 | 31.74 cr | 3.19 cr | 2.47 cr | 2.47 |
| 2024-12-31 | 26.46 cr | -2.54 cr | -2.80 cr | -2.80 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 146.96 cr | 8.28 cr | 2.08 cr | 0.30 |
| 2025-03-31 | 109.66 cr | 4.89 cr | 0.85 cr | 0.85 |
| 2024-03-31 | 91.93 cr | 0.14 cr | -1.79 cr | -1.79 |
| 2023-03-31 | 111.32 cr | -8.02 cr | -8.25 cr | -8.25 |
| 2022-03-31 | 263.27 cr | 62.90 cr | 45.31 cr | 44.96 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 196.16 cr | 1.46 cr | 2.26 cr | 180.76 cr |
| 2025-03-31 | 209.98 cr | 3.24 cr | 4.97 cr | 194.28 cr |
| 2024-03-31 | 205.16 cr | 14.06 cr | 2.52 cr | 193.11 cr |
| 2023-03-31 | 206.58 cr | 0.50 cr | 3.33 cr | 194.88 cr |
| 2022-03-31 | 219.13 cr | 8.25 cr | 4.40 cr | 203.20 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 3.30 cr | -3.53 cr | n/a |
| 2025-03-31 | -19.08 cr | -23.41 cr | n/a |
| 2024-03-31 | -2.71 cr | -3.80 cr | n/a |
| 2023-03-31 | 10.23 cr | 9.83 cr | n/a |
| 2022-03-31 | 1.40 cr | -4.60 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +68.09% | +0.11% | +0.24% | +0.00% | +31.57% | +0.00% |
| 2026-03-31 | +68.09% | +0.28% | +0.24% | +0.00% | +31.39% | +0.00% |
| 2026-01-07 | +68.09% | +0.08% | +0.04% | +0.00% | +31.79% | +0.00% |
| 2025-12-31 | +64.97% | +0.08% | +0.04% | +0.00% | +34.91% | +0.00% |
| 2025-09-30 | +64.97% | +0.07% | +0.04% | +0.00% | +34.92% | +0.00% |
| 2025-06-30 | +64.33% | +0.07% | +0.04% | +0.00% | +35.56% | +0.00% |
| 2025-03-31 | +64.30% | +1.07% | +0.04% | +0.00% | +34.59% | +0.00% |
| 2024-12-31 | +64.06% | +0.36% | +0.04% | +0.00% | +35.54% | +0.00% |
| 2024-09-30 | +63.77% | +0.69% | +0.04% | +0.00% | +35.50% | +0.00% |
| 2024-06-30 | +63.24% | +0.07% | +0.04% | +0.00% | +36.65% | +0.00% |
| 2024-03-31 | +63.24% | +0.07% | +0.02% | +0.00% | +36.67% | +0.00% |
| 2023-12-31 | +63.24% | +0.07% | +0.02% | +0.00% | +36.67% | +0.00% |
| 2023-09-30 | +63.24% | +0.10% | +0.02% | +0.00% | +36.65% | +0.00% |
| 2023-06-30 | +62.98% | +0.10% | +0.02% | +0.00% | +36.90% | +0.00% |
| 2023-03-31 | +62.98% | +0.10% | +0.02% | +0.00% | +36.90% | +0.00% |
| 2022-12-31 | +62.98% | +0.10% | +0.03% | +0.00% | +36.88% | +0.00% |
| 2022-09-30 | +70.00% | +1.67% | +0.58% | +0.00% | +27.74% | +0.00% |
| 2022-06-30 | +70.00% | +0.00% | +17.26% | n/a | n/a | +0.00% |
| 2022-03-31 | +70.00% | +0.00% | +17.45% | n/a | n/a | +0.00% |
| 2021-12-31 | +70.00% | +0.00% | +18.54% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 424,658.30 cr | 35.053345 | +15.50% | +3.72% |
| DIVISLAB | DIVI S LABORATORIES LTD | 267,167.60 cr | 91.684145 | +18.37% | +47.91% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,377.11 cr | 74.094685 | +16.87% | +28.16% |
| LAURUSLABS | LAURUS LABS LIMITED | 125,408.69 cr | 114.827348 | +21.77% | +138.16% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 124,833.39 cr | 27.818646 | +16.04% | +26.46% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 121,354.29 cr | 57.614911 | +22.62% | +7.87% |
| DRREDDY | DR. REDDY S LABORATORIES | 113,923.95 cr | 40.698752 | +7.80% | +14.41% |
| CIPLA | CIPLA LTD | 112,841.65 cr | 38.950805 | +8.80% | -7.58% |
Try these prompts
- Analyze NURECA with valuation, momentum and industry peers
- Compare NURECA with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare NURECA with other Healthcare stocks
Data snapshot: 2026-11-03. Not investment advice.